These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30132537)

  • 1. Microarray and pattern miner analysis of AXL and VIM gene networks in MDA‑MB‑231 cells.
    Natarajan S; Sumantran VN; Ranganathan M; Madheswaran S
    Mol Med Rep; 2018 Oct; 18(4):4147-4155. PubMed ID: 30132537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
    Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
    Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
    Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
    Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.
    Vuoriluoto K; Haugen H; Kiviluoto S; Mpindi JP; Nevo J; Gjerdrum C; Tiron C; Lorens JB; Ivaska J
    Oncogene; 2011 Mar; 30(12):1436-48. PubMed ID: 21057535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
    Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
    Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
    Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
    Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
    Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
    Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes.
    Kohn KW; Zeeberg BR; Reinhold WC; Sunshine M; Luna A; Pommier Y
    PLoS One; 2012; 7(5):e35716. PubMed ID: 22570691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
    Seike M; Kim CH; Zou F; Noro R; Chiba M; Ishikawa A; Κunugi S; Kubota K; Gemma A
    Oncol Rep; 2017 Jun; 37(6):3261-3269. PubMed ID: 28440492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
    Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
    World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Expression of Vimentin and Axl in Breast Cancer.
    Tanaka K; Tokunaga E; Inoue Y; Yamashita N; Saeki H; Okano S; Kitao H; Oki E; Oda Y; Maehara Y
    Clin Breast Cancer; 2016 Dec; 16(6):520-526.e2. PubMed ID: 27506606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
    Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
    Ozyurt R; Ozpolat B
    Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
    Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
    Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
    Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.